Whole body hyperthermia and intraperitoneal carboplatin in residual ovarian cancer

Intraperitoneal (IP) cisplatin-based chemotherapy provides prolonged disease-free survival in some women with residual peritoneal ovarian cancer following systemic chemotherapy. This review presents several considerations which support the combined use of IP carboplatin and whole body hyperthermia in this patient population. This novel treatment approach is predicated on projected advantages which relate to improved therapeutic index.